Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FTα CRISPR/Cas9 KO Plasmid (h): sc-403920
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FTα CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the FTα genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FTα Antibody (D-5): sc-374262
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FTα CRISPR/Cas9 KO Plasmid (h) | sc-403920 | 20 µg | $397.00 |
Overview
FNTA encodes the alpha subunit of protein farnesyltransferase (FTα), which heterodimerizes with FNTB to catalyze farnesylation of C-terminal CaaX motif proteins. This lipid modification promotes membrane association, subcellular trafficking, and protein–protein interactions for key signaling regulators including RAS family GTPases and nuclear lamins. Through control of prenylated substrate localization and stability, FTα contributes to pathways governing proliferation, cytoskeletal dynamics, vesicle transport, and stress responses. Dysregulated prenylation and aberrant RAS/lamin signaling have been linked to oncogenic signaling, premature aging phenotypes, and other disorders where membrane-dependent signaling and nuclear architecture are perturbed.
FTα CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the FNTA gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the FNTA together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the FNTA open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish FTα protein expression.
This CRISPR knockout system enables efficient generation of FNTA-deficient cell models for investigation of FTα signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting FNTA exon(s) critical for FTα function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple FNTA genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by FTα CRISPR/Cas9 KO Plasmid (h) and FTα CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the FNTA locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by FTα HDR Plasmid (h) and FTα HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by FNTA homology arms to support homology-directed repair at defined FNTA target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.